Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Clinical trial NCT07589699 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07589699
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Breast Cancer HER2-positive Breast Cancer Early-stage Breast Cancer Locally Advanced Breast Cancer

Start date: 2026-05-31
Primary completion: 2028-12-31
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.